4-(benzyloxy)-6-chloro-3H-imidazo[4,5-c]pyridine | 52559-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-(benzyloxy)-6-chloro-3H-imidazo[4,5-c]pyridine
• 英文别名: 6-benzyloxy-2-chloroimidazo[4,5-c]pyridine；6-chloro-4-phenylmethoxy-1H-imidazo[4,5-c]pyridine
• CAS: 52559-19-0
• 化学式: C₁₃H₁₀ClN₃O
• 分子量: 259.695
• InChiKey: ZIFXPLLDFKUDHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(benzyloxy)-6-chloro-3H-imidazo[4,5-c]pyridine 在 四丁基碘化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 2-(3,4-dichlorobenzylamino)-7-(4-methoxybutyl)-6-oxo-3-deazapurine
  参考文献：
  名称：

  7-Alkyl-N2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity

  摘要：

  Several 2-anilino- and 2-benzylamino-3-deaza-6-oxopurines [3-deazaguanines] and selected 8-methyl and 8-aza analogs have been synthesized. 7-Substituted N-2-(3-ethyl-4-methylphenyl)-3-deazaguanines were potent and selective inhibitors of Gram+ bacterial DNA polymerase (pol) IIIC, and 7-substituted N-2-(3,4-dichlorobenzyl)-3-deazaguanines were potent inhibitors of both pol IIIC and pol IIIE from Gram+ bacteria, but weakly inhibited pol IIIE from Gram- bacteria. Potent enzyme inhibitors in both classes inhibited the growth of Gram+ bacteria (MICs 2.5-10 mu g/ml), and were inactive against the Gram- organism Escherichia coli. Several derivatives had moderate protective activity in Staphylococcus aureus-infected mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.093
• 作为产物：
  描述：

  3,4-二氨基-2,6-二氯吡啶盐酸盐 在 sodium 、 乙酸酐 作用下， 反应 0.5h， 生成 4-(benzyloxy)-6-chloro-3H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  7-Alkyl-N2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity

  摘要：

  Several 2-anilino- and 2-benzylamino-3-deaza-6-oxopurines [3-deazaguanines] and selected 8-methyl and 8-aza analogs have been synthesized. 7-Substituted N-2-(3-ethyl-4-methylphenyl)-3-deazaguanines were potent and selective inhibitors of Gram+ bacterial DNA polymerase (pol) IIIC, and 7-substituted N-2-(3,4-dichlorobenzyl)-3-deazaguanines were potent inhibitors of both pol IIIC and pol IIIE from Gram+ bacteria, but weakly inhibited pol IIIE from Gram- bacteria. Potent enzyme inhibitors in both classes inhibited the growth of Gram+ bacteria (MICs 2.5-10 mu g/ml), and were inactive against the Gram- organism Escherichia coli. Several derivatives had moderate protective activity in Staphylococcus aureus-infected mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.093

文献信息

• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• [EN] PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES<br/>[FR] IMIDAZO[4,5-C]PYRIDINES A ACTIVITE PHARMACOLOGIQUE
  申请人：ALTANA PHARMA AG

  公开号：WO2005026164A1

  公开（公告）日：2005-03-24

  The invention relates to 6-substituted imidazo[4,5-c]pyridines of formula 1, in which X is O (oxygen) or NH and Y has either the meaning -CH2-AR or Y denotes the group gp (gp) wherein Z has the meaning -CHR8- or -CHR8-CHR9-. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  这项发明涉及式1中的6-取代咪唑并[4,5-c]吡啶，其中X为O（氧）或NH，Y具有含义-CH2-AR或Y表示该组gp（gp），其中Z具有含义-CHR8-或-CHR8-CHR9-。这些化合物具有抑制胃酸分泌和优异的胃肠保护作用特性。
• Purine and isosteric antibacterial compounds
  申请人：——

  公开号：US20040014773A1

  公开（公告）日：2004-01-22

  The invention features 2,7-disubstituted purines and their isosteres such as the corresponding 3-deazapurines and 3-deaza-8-azapurines. The compounds disclosed herein have potent anti-microbial, e.g., anti-bacterial and anti-mycoplasmal properties. The compounds described herein inhibit DNA polymerase IIIC and DNA polymerase IIIE species; the compounds thus inhibit the growth of bacteria and mycoplasmata. The compounds can be administered to prevent or to treat Gram-positive or Gram-negative bacterial or mycoplasmal infections, e.g., in eukaryotic cell cultures, animals, or humans.

  本发明涉及2,7-二取代嘌呤及其异构体，如相应的3-去氮嘌呤和3-去氮-8-氮杂嘌呤。本文所披露的化合物具有强大的抗微生物，例如抗细菌和抗支原体的特性。本文所描述的化合物抑制DNA聚合酶IIIC和DNA聚合酶IIIE物种；因此，这些化合物抑制了细菌和支原体的生长。这些化合物可用于预防或治疗革兰氏阳性或革兰氏阴性细菌或支原体感染，例如在真核细胞培养物、动物或人类中。
• Pharmacologically active imidazo[4,5-c] pyridines
  申请人：Chiesa M. Vittoria

  公开号：US20060194782A1

  公开（公告）日：2006-08-31

  The invention relates to imidazo[4,5-c]pyridines of formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

  本发明涉及公式1的咪唑并[4,5-c]吡啶，其中取代基和符号具有说明书中所指示的含义。该化合物具有抑制胃酸分泌和优异的胃肠保护作用性质。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。